Tom accidentally took eight times the recommended dose of a fake version of retatrutide and says he nearly ended up in hospital
Excitement around the creation of a new drug, especially one showing early promise in clinical trials, is often celebrated by those developing it.
But new weight-loss drug retatrutide has become a headache not only for Eli Lilly, the pharmaceutical company behind it, but for regulators in the UK and around the world.
The jab has not yet been approved for human use by any regulatory body.
But illicit, counterfeit dupes of retatrutide are currently flooding the black market.
Experts have told the BBC this is one of the first times they have seen copycat versions of an experimental drug, still in the throes of being tested, become so widely available.
Vials purporting to be "reta" as it's become known, are being sold in the UK in gyms, nail and beauty salons, hairdressers, on social media and even by flower sellers on the street.
"The world has gone mad," pharmacist and director of 24 HR Pharmacy, Sehar Shahid says. "People are effectively injecting an illegal drug and thinking it's safe.
"It's become so normalised people openly talk about their dealers, where's best to get it from and post all over social media."
One quick flick through my socials and I can order a batch of a drug billed as retatrutide in minutes – although I would have no proof what it's actually made of, what its effects would be and where it's come from.
Keen users are posting before and after "reta" pics on their TikTok feeds, describing how it has silenced food noise, helped them shed pounds and lose inches, with some saying it's completely transformed their lives.
The problem? Despite positive results in its most recent clinical trials, real retatrutide is still being tested for its safety and efficacy.
Only 50% of drugs in this Phase III stage of testing in the US are eventually approved by the Food and Drug Administration (FDA), so there is no guarantee retatrutide will ever hit the market. The high rate of failure is primarily down to drugs not working as well in large, diverse human populations as they do in smaller early tests, or because they reveal unexpected safety hazards.
And the current, fake versions available may not resemble what's being developed in the safe confines of the laboratory.
The UK's medicines regulator found more than 2,000 unlicensed retatrutide pens during a raid on an illegal weight loss drug factory in Northampton last year
